Novo Nordisk to acquire Canadian pharma company Inversago Pharma
Danish pharma major Novo Nordisk A/S has confirmed its plan to acquire Montreal-based Inversago Pharma. The potential cash deal, reaching up to $1.075 billion, hinges ... Read More
Inversago Pharma’s INV-202 shows promising effects in metabolic syndrome
Inversago Pharma, a Canadian clinical stage company, has announced positive data from its Phase 1b trial for INV-202, a peripherally-acting CB1r blocker, which is being ... Read More